Abstract
With the significant increase in treatment of hypogonadism and the use of testosterone therapy, hormone management has evolved into a complicated topic, requiring specialized knowledge. When patients’ testosterone levels rise, aromatase converts testosterone into estrogen, leading to rising estrogen levels. Though the AUA guidelines mention the use of aromatase inhibitors as an option, and mention hyperestrogenemia as a risk of testosterone therapy, no further guidelines regarding management of hyperestrogenemia or hypoestrogenemia are provided. We aim to assess the variability in management of estrogen levels in men treated with testosterone therapy. An anonymous survey was sent to the membership of ISSM using survey monkey. The survey included questions on respondent demographics, including time practicing urology, and practice location, type, and specialty. In addition, we asked respondents their approach to management of estrogen in patients receiving testosterone therapy. Responses to the surveys were collected and tabulated using Survey Monkey (San Mateo, California, USA). Chi-square test was used to determine association between categorical variables.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
